Ro 22-9194

structure given in first source; RN given for (+-)-isomer; RN for compound without isomeric designation not available 10/92

Also Known As:

2-amino-N-(2,6-dimethylphenyl)-N-(3-(3-pyridyl)propyl)propionamide; Ro-22-9194

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Ventricular Tachycardia 11/01/1996 - "Ro 22-9194 (20 and 30 mg/kg) also dose-dependently reduced the incidence of ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation, after coronary reperfusion. "
2.	Ventricular Fibrillation 11/01/1996 - "The incidence of ventricular fibrillation induced by reperfusion after a 30-min coronary ligation was significantly reduced by an i.v. infusion of Ro 22-9194 (10 mg/kg for 5 min before and an additional 20 mg/kg for 30 min during coronary ligation: total, 30 mg/kg) from 73% in the vehicle-treated group to 13%. " 11/01/1996 - "Ro 22-9194 (20 and 30 mg/kg) also dose-dependently reduced the incidence of ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation, after coronary reperfusion. "
3.	Ischemia 11/01/1996 - "Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity."

1.	Ligation